About Us

The European NF-κB subunit workshops

The NF-κB subunit workshop to be held in Espinho in October 2020 is the 5th in a highly successful series. The first of these was held in Rauischholzhausen, Germany in 2012 and was founded as a reaction to the perceived lack of coverage of this important area of biology at other international conferences. Following the very positive feedback from this first workshop, this was followed by the second in the series in Pitlochry, Scotland in 2014, the third in Corfu, Greece in 2016 and the fourth in Grasse, France in 2018.

The ethos of the workshops is to bring together researchers interested in the biology of the NF-κB subunits from all over Europe (and sometimes beyond) in an informal and relaxed setting to present and discuss unpublished work from their laboratories. The workshop is entirely self-funded, relying on registration fees from participants and sponsorship from interested companies and organisations. We encourage talks from scientists at all stages of their careers and our aim is to provide an opportunity for as many as possible of those who wish to present their data to be able to do so. A key objective of these meetings it to encourage collaborations leading to scientific publications and grant funding.

The subject areas covered at the workshops are diverse. These include fundamental mechanistic studies of the NF-κB proteins function as transcription factors, including proteomic analysis of subunit post-translational modifications and genome wide analysis of genetic targets through ChIP Seq and RNA Seq analysis. Another focus of the workshops is the physiological and pathological roles of the NF-κB subunits. Data presented includes those using mice and other model systems, together with analysis of normal and diseased human tissues. We have sessions devoted to the role of NF-κB in the immune and inflammatory responses as well as its role in cancer.

To illustrate this diversity selected presentations from the first four meetings include:

Regulation of immune responses by NF-κB1 p105 proteolysis: Steven Ley (London)
Systems Biology analysis of NF-κB signalling: Mike White (Manchester)
Regulation of NF-κB in the nucleus by protein kinases: Lienhard Schmitz (Giessen)
NF-κB1 regulates neutrophil inflammation and progression to cancer in liver disease: Derek Mann (Newcastle)
NF-κB and HIF crosstalk: Sonia Rocha (Dundee)
NF-κB regulation by the protease MALT1 in lymphocytes and lymphoma cells: Stephan Hailfinger (Lausanne)
Regulation of adipogenesis by lymphotoxin signaling and RelB: Falk Weih (Jena)

Evolution of NF-κB: Thomas Gilmore (Boston)
Genome wide organization of cytokine-driven enhancers by TAK1-p65 NF-κB-dependent pathways: Michael Kracht, (Giessen)
Stochastic NF-κB -dependent interchromosomal interactions coordinate the antiviral transcriptional program: Dimitris Thanos (Athens)
Identification of an NF-κB -dependent CD38 positive feedback loop in chronic lymphocytic leukemia (CLL): Liam Morgan (Cardiff)
Dynamics and Consequences of RelA Phosphorylation: Claire Eyers (Liverpool)
Control of ikba/rela regulation by deubiquitinylases: Michael Naumann (Magdeburg)

Phosphatase-mediated regulation of canonical NF-κB in T-cell lymphomas: Luis Espinosa (Barcelona)
Assessment of RelB phosphorylation on serine 472 as a new marker of triple-negative breast cancer aggressiveness: Veronique Baud (Paris)
BCL3, a 19q passenger in glioma that predicts response to alkylating chemotherapy via NF-κB dimer exchange: Bakhtiar Yamini (Chicago)
Accumulation of RelA in nucleolar aggresomes in response to proteotoxic stress: Lesley Stark (Edinburgh)
Using mouse models to investigate new and unexpected functions for NF-κB subunits in cancer: Neil Perkins (Newcastle)

Regulation of NF-κB in inflammation and immunity: Sankar Ghosh (New York)
Regulation of T cell development and function by NF-κB signalling: Benedict Seddon (London)
Combinatorial specificity of NF-κB transcription factor binding and function: Simona Saccani (Nice)
Modes and mechanisms of subunit specificity and precursor conversion in oncogenic NF-κB signaling: Claus Scheidereit (Berlin)
Novel human inborn errors of the NF-κB pathway and their clinical impact: Anne Puel (Paris)
Microenvironmental NF-κB activity in T-cell leukemia development: Nuno dos Santos (Porto)